Market Overview

Synergy Pharmaceuticals to Initiate Phase 2 Study of SP-333 for Opioid-Induced Constipation


Synergy Pharmaceuticals (NASDAQ: SGYP) today announced plans to move
forward this quarter with SP-333, its proprietary next-generation
guanylate cyclase-C (GC-C) agonist, into a phase 2 study for the
treatment of opioid-induced constipation (OIC).

“The start of this trial represents the ongoing progress being made in
the clinical development of our novel GC-C agonist platform in multiple
gastrointestinal indications,” said Dr. Gary S. Jacob, President and
Chief Executive Officer of Synergy Pharmaceuticals Inc. “We recognize a
significant market opportunity for new OIC drug candidates and believe
SP-333 has excellent potential to address the unmet medical needs of
these patients. We look forward to evaluating the potential role of
SP-333 for OIC as part of our

See full press release

Posted-In: News Guidance Financing Contracts Management Global


Related Articles (SGYP)

View Comments and Join the Discussion!